Last reviewed · How we verify
Antiarrhythmic drug (AAD)
Antiarrhythmic drugs work by modulating cardiac electrical activity to restore normal heart rhythm.
Antiarrhythmic drugs work by modulating cardiac electrical activity to restore normal heart rhythm. Used for Atrial fibrillation, Ventricular arrhythmias, Supraventricular tachycardia.
At a glance
| Generic name | Antiarrhythmic drug (AAD) |
|---|---|
| Also known as | Brand names; Tambocor, Pronon, Sotacor, Ancaron |
| Sponsor | Kyoto University, Graduate School of Medicine |
| Drug class | Antiarrhythmic agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Antiarrhythmic drugs suppress abnormal electrical impulses in the heart that cause irregular heartbeats. They work through various mechanisms including sodium channel blockade, beta-adrenergic antagonism, potassium channel blockade, or calcium channel inhibition, depending on the specific drug class. By slowing conduction velocity or prolonging refractory periods, they help restore coordinated electrical activity and normal sinus rhythm.
Approved indications
- Atrial fibrillation
- Ventricular arrhythmias
- Supraventricular tachycardia
Common side effects
- Bradycardia
- Hypotension
- Dizziness
- Proarrhythmic effects
- Gastrointestinal disturbances
Key clinical trials
- Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (NA)
- The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients (PHASE4)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation (NA)
- Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System (NA)
- Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control
- Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiarrhythmic drug (AAD) CI brief — competitive landscape report
- Antiarrhythmic drug (AAD) updates RSS · CI watch RSS
- Kyoto University, Graduate School of Medicine portfolio CI